BACKGROUND: In prostate cancer (PCa), lack of androgen receptor (AR) regulated TMPRSS2-ETS-related gene (ERG) gene fusion (ERGnegative ) status has been associated with African American race; however, the implications of ERG status for the location of dominant tumors within the prostate remains understudied. METHODS: An African American-enriched multiinstitutional cohort of 726 PCa patients consisting of both African American men (AAM; n = 254) and European American men (EAM; n = 472) was used in the analyses. Methods of categorical analysis were used. Messenger RNA (mRNA) expression differences between anterior and posterior tumor lesions were analyzed using Wilcoxon rank-sum tests with multiple comparison corrections. RESULTS: Anti-ERG immunohistochemistry staining showed that the association between ERG status and anterior tumors is independent of race and is consistently robust for both AAM (ERGnegative 81.4% vs. ERGpositive 18.6%; p = .005) and EAM (ERGnegative 60.4% vs. ERGpositive 39.6%; p < .001). In a multivariable model, anterior tumors were more likely to be IHC-ERGnegative (odds ratio [OR]: 3.20; 95% confidence interval [CI]: 2.14-4.78; p < .001). IHC-ERGnegative were also more likely to have high-grade tumors (OR: 1.73; 95% CI: 1.06-2.82; p = .02). In the exploratory genomic analysis, mRNA expression of location-dependent genes is highly influenced by ERG status and African American race. However, tumor location did not impact the expression of AR or the major canonical AR-target genes (KLK3, AMACR, and MYC). CONCLUSIONS: ERGnegative tumor status is the strongest predictor of anterior prostate tumors, regardless of race. Furthermore, AR expression and canonical AR signaling do not impact tumor location.
BACKGROUND: In prostate cancer (PCa), lack of androgen receptor (AR) regulated TMPRSS2-ETS-related gene (ERG) gene fusion (ERGnegative ) status has been associated with African American race; however, the implications of ERG status for the location of dominant tumors within the prostate remains understudied. METHODS: An African American-enriched multiinstitutional cohort of 726 PCa patients consisting of both African American men (AAM; n = 254) and European American men (EAM; n = 472) was used in the analyses. Methods of categorical analysis were used. Messenger RNA (mRNA) expression differences between anterior and posterior tumor lesions were analyzed using Wilcoxon rank-sum tests with multiple comparison corrections. RESULTS: Anti-ERG immunohistochemistry staining showed that the association between ERG status and anterior tumors is independent of race and is consistently robust for both AAM (ERGnegative 81.4% vs. ERGpositive 18.6%; p = .005) and EAM (ERGnegative 60.4% vs. ERGpositive 39.6%; p < .001). In a multivariable model, anterior tumors were more likely to be IHC-ERGnegative (odds ratio [OR]: 3.20; 95% confidence interval [CI]: 2.14-4.78; p < .001). IHC-ERGnegative were also more likely to have high-grade tumors (OR: 1.73; 95% CI: 1.06-2.82; p = .02). In the exploratory genomic analysis, mRNA expression of location-dependent genes is highly influenced by ERG status and African American race. However, tumor location did not impact the expression of AR or the major canonical AR-target genes (KLK3, AMACR, and MYC). CONCLUSIONS: ERGnegative tumor status is the strongest predictor of anterior prostate tumors, regardless of race. Furthermore, AR expression and canonical AR signaling do not impact tumor location.
Authors: Michael Kongnyuy; Abhinav Sidana; Arvin K George; Akhil Muthigi; Amogh Iyer; Michele Fascelli; Meet Kadakia; Thomas P Frye; Richard Ho; Francesca Mertan; M Minhaj Siddiqui; Daniel Su; Maria J Merino; Baris Turkbey; Peter L Choyke; Bradford J Wood; Peter A Pinto Journal: Urol Oncol Date: 2016-02-20 Impact factor: 3.498
Authors: Ricardo F Sanchez-Ortiz; Patricia Troncoso; Richard J Babaian; Josep Lloreta; Dennis A Johnston; Curtis A Pettaway Journal: Cancer Date: 2006-07-01 Impact factor: 6.860
Authors: Joachim Weischenfeldt; Ronald Simon; Lars Feuerbach; Karin Schlangen; Dieter Weichenhan; Sarah Minner; Daniela Wuttig; Hans-Jörg Warnatz; Henning Stehr; Tobias Rausch; Natalie Jäger; Lei Gu; Olga Bogatyrova; Adrian M Stütz; Rainer Claus; Jürgen Eils; Roland Eils; Clarissa Gerhäuser; Po-Hsien Huang; Barbara Hutter; Rolf Kabbe; Christian Lawerenz; Sylwester Radomski; Cynthia C Bartholomae; Maria Fälth; Stephan Gade; Manfred Schmidt; Nina Amschler; Thomas Haß; Rami Galal; Jovisa Gjoni; Ruprecht Kuner; Constance Baer; Sawinee Masser; Christof von Kalle; Thomas Zichner; Vladimir Benes; Benjamin Raeder; Malte Mader; Vyacheslav Amstislavskiy; Meryem Avci; Hans Lehrach; Dmitri Parkhomchuk; Marc Sultan; Lia Burkhardt; Markus Graefen; Hartwig Huland; Martina Kluth; Antje Krohn; Hüseyin Sirma; Laura Stumm; Stefan Steurer; Katharina Grupp; Holger Sültmann; Guido Sauter; Christoph Plass; Benedikt Brors; Marie-Laure Yaspo; Jan O Korbel; Thorsten Schlomm Journal: Cancer Cell Date: 2013-02-11 Impact factor: 31.743
Authors: Michelle I Echevarria; Shivanshu Awasthi; Chia-Ho Cheng; Anders E Berglund; Robert J Rounbehler; Travis A Gerke; Mandeep Takhar; Elai Davicioni; Eric A Klein; Stephen J Freedland; Ashley E Ross; Edward M Schaeffer; Robert B Den; John L Cleveland; Jong Y Park; Walter Rayford; Kosj Yamoah Journal: J Urol Date: 2019-07-08 Impact factor: 7.450
Authors: R Bhatia-Gaur; A A Donjacour; P J Sciavolino; M Kim; N Desai; P Young; C R Norton; T Gridley; R D Cardiff; G R Cunha; C Abate-Shen; M M Shen Journal: Genes Dev Date: 1999-04-15 Impact factor: 11.361
Authors: Theresa M Koppie; Fernando J Bianco; Kentaro Kuroiwa; Victor E Reuter; Bertrand Guillonneau; James A Eastham; Peter T Scardino Journal: BJU Int Date: 2006-10-09 Impact factor: 5.588
Authors: Kathryn L Penney; Andreas Pettersson; Irene M Shui; Rebecca E Graff; Peter Kraft; Rosina T Lis; Howard D Sesso; Massimo Loda; Lorelei A Mucci Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-03-03 Impact factor: 4.254
Authors: Jordan H Creed; Anders E Berglund; Robert J Rounbehler; Shivanshu Awasthi; John L Cleveland; Jong Y Park; Kosj Yamoah; Travis A Gerke Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-11-22 Impact factor: 4.254
Authors: Anders E Berglund; Robert J Rounbehler; Travis Gerke; Shivanshu Awasthi; Chia-Ho Cheng; Mandeep Takhar; Elai Davicioni; Mohammed Alshalalfa; Nicholas Erho; Eric A Klein; Stephen J Freedland; Ashley E Ross; Edward M Schaeffer; Bruce J Trock; Robert B Den; John L Cleveland; Jong Y Park; Jasreman Dhillon; Kosj Yamoah Journal: Prostate Cancer Prostatic Dis Date: 2018-10-26 Impact factor: 5.554